Biotia Raises $2.4M in Seed Funding
Summary
The company intends to use the funds to further develop and implement its diagnostic testing methods, including its AI-based software Chelsea™. Led by Dr. Niamh B. O’Hara (Co-Founder, and CEO), Dr. Christopher E. Mason (Co-Founder, Global Director, and Associate Professor at Weill Cornell Medicine), Dr. Rachid Ounit (Co-Founder, and CTO) and Dr. Dorottya Nagy-Szakal (Chief Medical Officer), Biotia leverages next-generation DNA sequencing (NGS) and artificial intelligence (AI) software for precision infectious disease detection and diagnosis. The company’s AI-based software, Chelsea™, can identify known and emerging bacteria, fungi, parasites and viruses from a clinically-curated and annotated database of over 16,000 microbial species, as well as antimicrobial resistance (AMR) genetic markers and virulence genetic markers. Chelsea’s engine offers a “precision metagenomic” test, including a complete report of the microbial profile and predicted drug resistance. Biotia plans to launch new CAP/CLIA clinical diagnostic tests in early 2020.